Overview
Corporate Mission Statement
CEO Message
Board of Directors
Key Employees
Corporate History
Awards |
Ash Access Technology, Inc. is an integrated
specialty pharmaceutical / medical device company engaged in the
development and commercialization of proprietary technologies and
devices to treat and prevent the clinical consequences of diseases
and disorders related to vascular access. The company has an advanced
portfolio of innovative products targeting catheter-related bloodstream
infections (CRBSI) and poor patency (blood flow) – the significant
challenges associated with the use of both acute and chronic catheters
for vascular access.
The company was founded in 2003 by Mr. Robert B.Truitt
(President & CEO) and Dr. Stephen R. Ash (Chaiman of the Board)
in Lafayette, IN. Our research and development programs are led
by the expertise and practical experience of Dr. Ash who has been
a practicing nephrologist for over 30 years. Dr. Ash is a world-recognized
researcher and thought-leader in the field of Nephrology / Interventional
Nephrology; patent holder in extracorporeal devices, sorbent chemistry,
and vascular / peritoneal access devices; and a founding member
of the ASDIN (American Society of Diagnostic & Interventional
Nephrology).
Our team’s comprehensive understanding of
vascular access devices, their complications and clinical consequences,
combined with the proven ability for product development and commercialization,
creates an organization that is well positioned to make a unique
and significant impact in the lives of patients suffering from the
consequences of vascular access complications. We are building our
commercial product portfolio to focus on breakthrough technologies
in areas with significant, unmet medical needs:
- Discovering, formulating, clinical testing and
commercializing a novel antimicrobial / antithrombotic
therapy (Zuragen™) for the prevention and treatment of
CRBSI as well as the eradication of biofilm.
- Building a dynamic hemodialysis and peritoneal dialysis catheter portfolio that includes an innovative curved tip design and other technological advances which provide significant differences from current catheters on the market.
- Pursuing the integration of Zuragen™ technology
with our catheter designs to form a novel eluting device that
creates a barrier for infection which would potentially last
months instead of days.
The commitment to fulfill our mission is also
evident by the substantial investment in our ongoing research and
development programs, established partnerships with industry leading
research organizations as well as our collaboration with thought-leaders and experts in the fields of Nephrology, Interventional Nephrology
and Infectious Disease. |